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Abstract: The alpha-1 antitrypsin (AAT) haplotype Pi*S, when inherited along with the Pi*Z 
haplotype to form a Pi*SZ genotype, can be associated with pulmonary emphysema in regular 
smokers, and less frequently with liver disease, panniculitis, and systemic vasculitis in a small 
percentage of people, but this connection is less well established. Since the detection of cases can 
allow the application of preventive measures in patients and relatives with this congenital disorder, 
the objective of this study was to update the prevalence of the SZ genotype to achieve accurate 
estimates of the number of Pi*SZ subjects worldwide, based on studies performed according to 
the following criteria: 1) samples representative of the general population, 2) AAT phenotyping 
characterized by adequate methods, and 3) selection of studies with reliable results assessed with 
a coefficient of variation calculated from the sample size and 95% confidence intervals. Studies 
fulfilling these criteria were used to develop tables and maps with an inverse distance-weighted 
(IDW) interpolation method, to provide numerical and geographical information of the Pi*SZ 
distribution worldwide. A total of 262 cohorts from 71 countries were included in the analysis. 
With the data provided by these cohorts, a total of 1,490,816 Pi*SZ were estimated: 708,792 
in Europe; 582,984 in America and Caribbean; 85,925 in Africa; 77,940 in Asia; and 35,176 
in Australia and New Zealand. Remarkably, the IDW interpolation maps predicted the Pi*SZ 
prevalence throughout the entire world even in areas lacking real data. These results may be useful 
to plan strategies for future research, diagnosis, and management of affected individuals.
Keywords: SERPINA1, alpha-1 antitrypsin deficiency, protease inhibitor, genetic epidemiology, 
SZ genotype, inverse distance-weighted interpolation, geographic information system
Introduction
Human alpha-1 antitrypsin (AAT) is a 52-kDa glycoprotein mainly secreted by 
hepatocytes. Its main physiological function is to protect the matrix proteins of the 
lungs (especially elastin) from the proteolytic effects of proteases (especially neutrophil 
elastase and proteinase 3) released by activated and dying neutrophils and serine 
proteases released by invading bacteria.1
Human AAT is codified by the SERPINA1 gene, located at the distal end of the 
long arm (q) of the fourteenth chromosome at position q31-32.3. This gene is orga-
nized into three noncoding exons (1A, 1B, and 1C), four coding exons (II–V), and six 
introns.2 The AAT gene has two alleles that are transmitted by recessive autosomal 
codominant Mendelian inheritance.3 SERPINA1 alleles are named with the prefix Pi* 
(protease inhibitor*).4 Normal alleles are designated Pi*M, and the most prevalent 
deficiency alleles are Pi*S and Pi*Z, or simply S and Z. Mutated S (Glu264Val) and 
Z (Glu342Lys) alleles produce proteins with conformational changes that polymerize 
in the rough endoplasmic reticulum of the producing cells, forming stable polymers 
that are retained within hepatocytes without being secreted into the bloodstream and 
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secondarily causing a decreased concentration of AAT in 
blood and tissues.5 The vast majority of genotypes found 
in clinical practice are combinations of M, S, and Z alleles, 
that is, Pi*MM (normal genotype present in ~85%–95% of 
people, expressing 100% of serum AAT), Pi*MS, Pi*SS, 
Pi*MZ, Pi*SZ, and Pi*ZZ (five deficiency genotypes pres-
ent in almost the remaining 5%–15% of the population, 
expressing ~80%, 60%, 55%, 40%, and 15% of AAT, 
respectively).6
Severe alpha-1 antitrypsin deficiency (AATD) has been 
defined by serum AAT levels 11 µM/L (measured by the 
purified standard used in the U.S. Registry) or 57 mg/dL 
measured by a commercial standard nephelometry (to convert 
micromolar to milligrams per deciliter you must multiply 
by a conversion factor of 5.2).7 This hereditary condition is 
characterized by an increased risk for chronic obstructive 
pulmonary disease (COPD) (ie, lung emphysema, persistent 
airflow obstruction, and/or chronic bronchitis) in adults; liver 
disease (ie, cholestasis, cirrhosis, and hepatocarcinoma) in 
children and adults; and much less frequently systemic vascu-
litis and neutrophilic panniculitis.7 In clinical practice, 96% of 
pathologies associated with AATD occur in homozygous ZZ, 
and the remaining 4% in heterozygous SZ and the extremely 
infrequent “rare” and “null” genotypes.8
The mean and 5th–95th percentile of AAT serum levels 
expressed by the SZ genotypes are 16 (10–23) µM/L9 which 
are equivalent to 83 (52–120) mg/dL. These mean serum 
levels of 16 µM/L are considered sufficient to protect the 
lungs from proteases; however, there is a 20% of Pi*SZ 
individuals with AAT serum levels 11 µM/L protective 
threshold who are at risk for AATD-related diseases.7 In fact, 
aggregating data from six studies demonstrated that the odds 
ratio (OR) for COPD in Pi*SZ compound heterozygotes 
compared with normal Pi*MM individuals was significantly 
increased at 3.26 (95% CI 1.24–8.57), these results show-
ing that the Pi*SZ genotype is a significant risk factor for 
COPD.10 Other studies have found that smoking entails a 
major risk for the development of COPD, but in the absence 
of smoking the risk of developing COPD by a Pi*SZ is 
negligible.11 Although no studies have been done to assess 
the effects of occupational and environmental pollutants on 
individuals with the SZ genotype, the ATS/ERS experts 
seem reasonable to assume that they can be as vulnerable as 
individuals with the Pi*ZZ type.6
The causal relationship of the SZ genotype with other 
pathologies other than lung emphysema is much more 
debatable.7
Because the incidence of SZ heterozygosity is so much 
higher than that of ZZ homozygosity, SZ heterozygosity may 
be an important public health problem, since the SZ geno-
type may favor the development of AATD-related diseases 
(especially COPD in smokers). Therefore, the objective of the 
present study was to update the epidemiological data about 
the prevalence and number of Pi*SZ genotypes, by means 
of detailed tables and IDW interpolation maps to provide the 
scientific community with up-to-date reliable information of 
the Pi*SZ distribution worldwide.
Methods
The methodology used in the present study was practically 
the same as that used by the authors for a recently published 
paper on genetic epidemiology of the AAT-Pi*Z allele/
genotype12 (the list of sources are available from the authors 
upon request).
sources of the control cohort data used 
in the present study
The present study used the available data from epidemiological 
studies performed to determine the frequencies of deficiency 
allele combinations for PI*S and PI*Z, in the healthy control 
cohorts of individual case studies worldwide. The manuscripts 
were obtained through a variety of sources, including searches 
of the peer-reviewed literature from 1965 up to March 2017 on 
PubMed, Web of Science, Embase, and Google Scholar data-
bases. Additional relevant studies were obtained by searching 
the bibliographies of the articles retrieved.12–23
study selection criteria
The criteria for selection and exclusion of studies for analysis 
were: 1) Samples representative of the general population; 
2) AAT phenotyping characterized by adequate methods, 
including isoelectric focusing (IEF), or, alternatively, crossed 
antigen–antibody electrophoresis or PCR; and 3) A coeffi-
cient of variation (CV) of the Pi*S and Pi*Z frequencies in 
each cohort to measure the precision of the results in terms 
of dispersion of the data around the mean. The value of this 
variable was adjusted for each country, according to the meth-
odology used in several previous peer-reviewed publications 
by our group. The following studies were excluded from the 
analysis: 1) Cohort studies of patients with AATD-related 
diseases (eg, COPD, liver cirrhosis, rheumatoid arthritis, 
arterial dissections, etc.); 2) Screening studies in which 
phenotypes were determined only in samples with AAT 
concentrations below any given cut-off point.12
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Calculation of Pi allelic frequency and 
genotypic prevalence
Gene frequency is defined as the frequency of all genes 
of a particular type, whether occurring in homozygotes or 
heterozygotes. The total number of alleles is twice the number 
of subjects. Therefore, the gene frequency was obtained by 
adding the number of S or Z alleles and expressing this total 
as a fraction of the total number of Pi alleles in the population 
(alleles per 1,000 genes of all Pi types).
The prevalence of the SZ genotype was calculated assum-
ing the population to be in Hardy–Weinberg equilibrium: 
p2 +2pq + q2 =1 (where p is the proportion of the Z allele 
and q is the proportion of the S allele).
In addition, 95% confidence intervals (95% CI) were 
calculated for allele frequencies, prevalence, and numbers 
of Pi*SZ.
Inverse distance-weighting (IDW) 
multivariate interpolation maps
Pi*SZ prevalence was used to develop maps using a 
geographic information system (GIS) of an inverse distance-
weighted (IDW) interpolation method. IDW interpolation 
is based on the assumption that the attributed value of an 
unsampled point is the weighted average of known values 
within the neighborhood, and the weights are inversely 
related to the distances between the prediction location 
and the locations sampled.24 With this approach, maps 
show quantitative diverging data (starting from zero or a 
reference value) displayed by two contrasting brightness 
red-blue ramps, with the darker colors at each end repre-
senting “the more positive” (red) and “the more negative” 
(blue).23 According to this concept, in this study, Pi*SZ 
prevalence was represented by scales of 10 colors (with 
the range of reds representing the highest prevalence; the 
range of yellow and green colors depicting intermediate 
prevalences; and blues representing the lowest prevalence). 
Since the different colors correspond to numerical values, 
they can easily be converted into quantitative data with 
the naked eye.
Results
selected cohorts and the number 
of subjects studied
A total of 262 cohorts (90 from Europe, 40 from America and 
Caribbean islands, 17 from Africa, 106 from Asia, 8 from 
Australia, and 1 from New Zealand) were selected. The CIA 
database comprised 71 of the 193 countries existing in the 
world. These cohorts included a total of 205,273 subjects, 
distributed as follows: 79,118 in America and Caribbean; 
75,603 in Europe; 38,682 in Asia; 5,031 in Africa; 5,536 in 
Australia, and 1,303 in New Zealand.
Prevalence and the number of Pi*sZ 
genotypes
Tables 1–5 show the population of each country and the 
corresponding Pi*S and Pi*Z frequencies (expressed per 
1,000, with 95% CI) extracted from the selected studies. 
These basic data were used to calculate the SZ prevalence 
(with the Hardy–Weinberg formula) and the number of SZ 
(with 95% CI) in each of the selected countries.
europe
In Europe (Table 1), the mean SZ prevalence by regions 
(from the highest to the lowest) was as follows: Southern 
Europe, 1 SZ per 483 subjects (1:483); Western Europe, 
1:581; Northern Europe, 1:1,492; Central Europe, 1:1,712; 
and Eastern Europe, 1:11,818.
The mean SZ prevalence by countries (from the highest 
to the lowest) was as follows: Portugal, 1:205; Spain, 1:278; 
Latvia, 1:354; France, 1:413; Republic of Ireland, 1:424; 
Belgium, 1:551; the Netherlands, 1:617; UK, 1:900; and it 
was over 1 per 1,000 in the rest of European countries, reach-
ing the minimum prevalence of almost 1:25,000 in Russia.
Consistent with the prevalence and number of inhabit-
ants, the total number of SZ in Europe was 708,792 and 
their distribution by regions (from highest to lowest) was 
as follows: Western Europe, 295,187; Southern Europe, 
291,856; Central Europe, 86,544; Northern Europe, 27,815; 
and Eastern Europe, 7,389.
By individual countries, the highest numbers were found 
in Spain (ie, 174,822), followed by France (161,680), UK 
(73,973), Italy (64,137), Germany (60,396), and Portugal 
(52,836). The SZ numbers in the other countries were 
very variable, but always much lower than the above 
mentioned.
america and Caribbean
In America (Table 2), the highest prevalence was found in 
Canada with 1 SZ per 907 subjects (1:907) and the USA 
(1:1,018). SZ prevalence was twice lower in Central and 
South America and Caribbean Islands, with an approximate 
mean value of ~1:2,000.
In concordance with the prevalence and number of inhab-
itants of each country, the total number of SZ was 582,984, 
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and the estimated number for geographic regions (from 
highest to lowest) was as follows: North America; 
343,229; South America; 207,446; Central America and 
Caribbean, 32,309.
By individual countries, the highest numbers were 
found in the non-Hispanic white population from USA 
(ie, 254,641), followed by Brazil (105,486), Mexico (49,590), 
Canada (38,997), Venezuela (25,103), Colombia (23,327), 
and Argentina (18,133). In the remaining countries, the 
numbers were very variable, but always much lower than 
the above mentioned.
africa
In Africa (Table 3), the highest prevalence was in Nigeria 
with 1 SZ per 2,209 subjects (1:2,209) and Somalia (1:2,509). 
Prevalence was three times lower in Cape Verde Islands. 
In the rest of African countries, the prevalence was so low 
that it was practically unmeasurable.
In concordance with the prevalence and the number 
of inhabitants of each country, the total number of SZ 
was 85,925; 98% of them in Nigeria; 1,437 in Somalia; 
175 in Morocco, and 88 in Cape Verde. Remarkably, in most 
African countries, no SZ genotypes were found.
asia
In Asia (Table 4), the highest prevalence was found in 
Thailand with 1 SZ per 1:2,247 subjects (1:2,247), followed 
by Pakistan (1:4,824) and Iran (1:9,614). In the remaining 
countries, the SZ prevalence was so low that it was practi-
cally unmeasurable.
In concordance with the prevalence and number of 
inhabitants of each country, the total number of SZ was 
77,940 (most of them in Pakistan and Thailand). Remark-
ably, in the vast majority of Asian countries, there were no 
SZ genotypes.
australia and new Zealand
In Australia and New Zealand (Table 5), the SZ prevalence 
was 1:840 and 1:574, respectively, both values being very 
similar to those found in the Republic of Ireland and UK.
In concordance with the prevalence and number of inhab-
itants, the calculated total number of SZ was 35,176 (27,380 
in Australia and 7,796 in New Zealand).
IDW interpolation maps of Pi*sZ 
prevalence
europe
Figure 1 shows an IDW interpolation map, with the Pi*SZ 
prevalence found in European countries. Black points indi-
cate the places where the studies that provided the data were 
conducted. Areas in dark red correspond to the regions of 
the highest prevalence, ranging from 1:205 in Portugal (the 
highest in the world) to ~1:300–500 in Spain, Latvia, France, 
and Republic of Ireland. Light red areas correspond to a 
prevalence range of 1:501–2,000. Dark yellow corresponds 
to a range of 1:2,001–2,500. Light yellow corresponds to a 
range of 1:2,501–5,000. Yellow green corresponds to a range 
of 1:5,001–25,000. Finally, medium blue and dark blue areas 
correspond to a range of 1:25,001–50,000 and 1:50,000, 
respectively.
Interpolation maps have the important advantage of being 
able to provide data from regions lacking studies, based on 
the available data from other neighboring regions. In this 
regard, some of the Canary Islands closer to the coasts of 
Morocco appear stained with light red and yellow, sug-
gesting that they may have a relatively high SZ prevalence 
of ~1:1,000–2,000. Belarus, western of Ukraine, Czech 
Republic, Slovakia, Hungary, or Croatia appear stained 
in light yellow, suggesting that they may have a moderate 
prevalence of SZ of ~1:2,500–5,000. The blue colors from 
Romania, Bulgaria, Turkey, mainland Greece, and its islands 
are indicative of very low prevalence (as is the case in the 
whole of northern Africa and the Middle East, included in 
this map for comparison).
america, africa, asia, australia, and new Zealand
Figure 2 shows a Pi*SZ prevalence IDW interpolation map 
of the world. Points indicate the places where the selected 
studies were conducted, and the 10-color scale is the same 
as previously described.
Table 5 estimated Pi*s and Pi*Z gene frequencies, Pi*sZ gene prevalence, and Pi*sZ number in australia and new Zealand
Geographic  
region (number 
of countries)
Country  
(total population)
Cohort  
number 
(size)
Pi*S frequency × 
1,000 (95% CI)
Pi*Z frequency × 
1,000 (95% CI)
Pi*SZ prevalence  
[1:x, Hardy– 
Weinberg] (95% CI)
Pi*SZ number  
(95% CI)
australia and 
new Zealand (2)
australia (22,992,654) 8 (5,536) 44 (41–48) 13 (11–16) 1:840 (656–1,077) 27,380 (21,349–35,068)
new Zealand (4,474,549) 1 (1,303) 39 (32–47) 22 (17–29) 1:574 (365–909) 7,796 (4,920–12,275)
Total 27,467,203 9 (6,839) 41 (37–47) 17 (14–22) 1:707 (510–993) 35,176 (26,269–47,343)
Abbreviation: CI, confidential interval.
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Outside Europe, there are very high SZ frequencies in 
large areas of Canada and the USA, which appear almost 
totally stained in red and yellow, except in some southern 
states stained in medium blue, such as Georgia (with a popula-
tion of African Americans, Asian Americans, Hispanics, and 
Latinos of 40%, very close to that of the American whites). 
There are also very high frequencies in the east and south of 
Australia, Tasmania, and throughout New Zealand.
In Central America, the Caribbean Islands, and South 
America, there are predominate yellow tones, indicative 
of a SZ intermediate mean prevalence of ~1:2,000, with 
the exception of Venezuela and Brazil that have a higher 
Figure 1 Distribution of sZ prevalence in europe.
Notes: In this IDW interpolation map of the Pi*sZ prevalence in european countries, black points indicate the places where the studies were conducted. The areas colored in 
red correspond to the regions with the highest prevalence (ie, south, west, and north of europe), those in yellow and green have moderate prevalences (eg, central europe), 
and those in blue (ie, Iceland and the most extreme regions of northern, southern, and eastern europe) are the areas with the lowest prevalences.
Abbreviation: IDW, inverse distance-weighted.
3L6=SUHYDOHQFHî
,':LQWHUSRODWLRQ
±±±±±±±±±!
Figure 2 Distribution of sZ prevalence in the world.
Notes: In this worldwide IDW interpolation map of Pi*sZ prevalence, black points indicate the places where the studies were conducted. The red areas correspond to the 
regions with the highest prevalences (eg, europe, large areas of the Usa and Canada, southeast australia, and new Zealand). Yellow areas indicate moderate prevalences 
(eg, Mexico, Central and south america, and isolated areas of africa and southeast asia). Finally, those colored in blues (such as africa, asia, and extreme regions of europe, 
north america, and australia) are regions with very low or nonexistent Pi*sZ prevalence.
Abbreviation: IDW, inverse distance-weighted.
3L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prevalence. However, the low number of points in Central 
America, the Caribbean, and South America significantly 
reduces the reliability of these findings.
Interestingly, several coastal regions bathed by the 
Indian Ocean, including the Horn of Africa (Somalia), Iran, 
Pakistan, and Thailand, appear stained with various shades 
of yellow, indicating moderate or low prevalence of SZ 
genotypes in these areas.
 In contrast, blue colors, indicative of very low or non-
existent SZ types, predominate in the Arctic regions, and in 
most parts of Russia, Asia, Indonesia, Africa, and northern 
Australia.
Discussion
The results of this analysis show that compound heterozy-
gous SZ is relatively frequent in Caucasian subjects living in 
Europe, the American continent, Australia, and New Zealand. 
Anecdotally, low or moderate values of SZ prevalence have 
been found in some countries populated by non-European 
people from West and Northeast Africa and South Asia. 
However, the paucity of available studies in these countries 
greatly reduces the reliability of the results. Interestingly, the 
IDW interpolation maps detected some unexpectedly high 
prevalence of SZ genotypes in numerous regions around 
the world completely lacking in studies, such as the Canary 
Islands, Eastern Europe, Mexico, Central and South America, 
Tasmania, etc., and also showed much higher prevalence 
than previously thought in the USA, Canada, Australia, and 
New Zealand.
Summarizing the findings of this study, it could be con-
cluded that of the ~1.5 million people with SZ genotype 
worldwide, 48% are in southern, western, northern, and central 
Europe; 39% in America (the majority in North America, 
Brazil, Venezuela, and Colombia); and the remaining 13% in 
white individuals residing in New Zealand and Australia, and 
in a small number of African and Asian subjects unevenly dis-
tributed throughout Africa, and western and southern Asia.
The authors are aware that, despite having tried to make 
the best possible selection of studies, the estimates of this 
study may have biases related to the composition of the 
samples studied, which included newborns, blood donors, 
school or college students, soldiers, hospital staff, persons 
undergoing pre-employment or routine medical examina-
tions, active workers, natives with specific genetic traits, 
a mixture of subjects generically called “healthy unrelated 
people,” etc. Really, only a few samples from a minority 
of studies were representative of the general population. 
Another bias that may distort the results of this study is 
that they were necessarily based on the available data of 
only 37% of all the countries in the world. IDW interpola-
tion maps were created to solve this problem, providing 
data to regions lacking these maps. In any case, the data 
estimated by IDW interpolation are much more reliable the 
greater the number of real data and the closer they are to one 
another. The points close to each other allow more precise 
estimates than distant points. Therefore, this technique is 
more reliable if the data are dense and evenly spaced. In 
this sense, in large regions of the world, such as South 
America, Africa, and large regions of Asia, not only data 
shortages were found but also large distances between points, 
which reduce the accuracy of these interpolated values. 
In addition, because IDW computes an average value, the 
value calculated for a non-sampled point can never be higher 
than the maximum value for a sample point or lower than 
the minimum value of the sample point, so this technique 
may be wildly inaccurate in some locations. Nevertheless, 
the findings of this study seem to be in accordance with the 
reported S and Z frequency distribution worldwide,12–23 and 
with the hypothesis that both deficiency alleles originate from 
Caucasians living in Europe at different historical times. It is 
believed that the Pi*Z mutation has a relatively recent origin 
in Caucasians living in northern Europe ~2,000 years or 66 
generations ago (one generation =30 years),25 and it was 
spread into the rest of the continent through maritime and 
inland waterways, via Baltic countries. On the other hand, it 
has been proposed that the S variant emerged in the Iberian 
Peninsula 300–450 generations ago (ie, 10–15,000 years 
ago), and in the Franco-Cantabrian refuge area during the last 
glacial era, spreading from there by people who later repopu-
lated Europe.26 Then, especially from the 16th-century AD, 
Europeans dispersed both genes for non-European countries 
to which they colonized or where they emigrated.
Since SZ genotypes express serum levels ranging from 10 
to 23 µM/L, and 20% of them express concentrations below 
the protective level of 11 µM7 leading experts on the subject 
have estimated that ~10% of SZ individuals may develop 
emphysema particularly if they have a history of smoking,27 
and besides a possibly smaller but unknown percentage of 
SZ, individuals may develop liver cirrhosis, systemic vascu-
litis, or panniculitis. Therefore, if these previous assumptions 
were true, 10% (ie, 150,000 of the 1.5 million estimated SZs 
in the world) would be at high risk for COPD.
Both PiZ and PiS proteins form polymers that are retained 
within the endoplasmic reticulum of hepatocytes causing 
continued cell stress, and over time cell death and repair, 
leading in some cases to liver damage, fibrosis, cirrhosis, 
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and carcinomas, whereas the lack of circulating protein pro-
motes the development of COPD.28,29 However, while in the 
Z mutation intracellular polymerization/retention occurs in 
85%–90% of the molecules, in the S mutation polymerization 
occurs at most in 60% of them.30 In addition, the dramatic 
conformational changes of the Z protein determine a loss of 
80% of its functional activity. In contrast, the conformational 
changes of the S protein are much less dramatic, having a 
normal serum half-life31 and an association rate constant 
for neutrophil elastase that is close to normal, retaining its 
inhibitory capacity unchanged.32
Interestingly, in AATD heterozygotes, the composi-
tion of their circulating AAT is inversely proportional to 
the amount of liver polymerization/retention of each type 
of AAT. For example, in a recent study, the percentage 
of Z protein in MZ patients was only 18% and that of S 
protein in MS patients was 37%.33 In this regard, although 
the composition of serum AAT in SZ patients has not been 
sufficiently studied, it seems logically reasonable to accept 
that it could be ~70% S and 30% Z. This would mean that 
some SZs with AAT levels close to the lower limit, having 
two-third of the circulating AAT of S-type (ie, efficient) and 
1/3 of Z-type (ie, poorly efficient), may be below the protec-
tive level, and therefore at increased risk for AATD-related 
disease development.
Pioneering researchers from Europe and the USA 
reported an increased risk of developing COPD in a short 
series of subjects with SZ phenotypes,34,35 and these results 
have been confirmed in subsequent studies.11,36
The data provided by some Registries of Patients with 
AATD have generally coincided with those findings. For 
example, researchers from the Spanish Registry of Patients 
with AATD reported the data of 348 Pi*ZZ, 100 Pi*SZ, and 
21 carriers of rare deficiency variants, noting that Pi*ZZ 
showed more severe impairment in lung function and younger 
age at baseline compared with Pi*SZ subjects.37 In this same 
way, an observational study in 547 ZZ and 547 SZ patients 
registered in the Spanish and Italian national registries 
showed that SZ patients were older at diagnosis and had 
better preserved lung function, despite a higher smoking 
consumption.38 Also, a comparative study between 63 PiSZ 
and 63 PiZZ subjects from the UK AATD registry showed 
that subjects with Pi*SZ type showed less emphysema on CT 
scans, more apical predominance, less abnormal respiratory 
physiology test results, but similar health status impairment 
compared with matched subjects Pi*ZZ.39
The massive neonatal screening conducted by Sveger 
et al between 1972 and 1974 in 200,000 Swedish newborns 
detected 127 individuals Pi*ZZ and 54 Pi*SZ, who has 
been followed up regularly.40 At age 26, SZ individuals (5% 
smokers) had normal lung function test results, and a negli-
gible percentage had marginal deviations in liver test results.41 
In subsequent checkups, the lung function and quality of life 
of SZ patients remained quite well preserved.42
In addition, a meta-analysis performed by Dahl et al 
showed that pooled data from six studies found that the 
OR for COPD of the SZ heterozygotes was moderately 
but significantly increased with respect to that of the MM 
subjects.10
Therefore, in the absence of definitive evidence, it is 
generally accepted that individuals who have the Pi*SZ 
genotype with serum AAT levels below the protective 
threshold value have an increased risk of developing lung 
disease, especially if they smoke or if they are exposed to 
occupational and environmental pollutants.6
The association between SZ heterozygosity and the risk 
of developing a chronic liver disease, panniculitis, and granu-
lomatosis with polyangiitis is controversial, but in any case 
incomparably smaller than that of homozygotes ZZ.7
In conclusion, compound heterozygous SZ is relatively 
frequent in Caucasian subjects resident in Europe, and 
in their descendants residing in the American continent, 
Australia, and New Zealand. Since ~10% of SZ individuals 
may develop emphysema particularly if they have a history 
of smoking,27 at least 150,000 of the 1.5 million estimated 
SZs in the world would be at high risk for COPD, and 
therefore, knowledge of the SZ prevalence of AATD in every 
community may be important for patients, physicians, and 
health authorities, to increase the diagnosis and to implement 
appropriate preventive measures.
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